UK experimental use exemptions: Part 2—the Bolar exemption

As mentioned in the first of this four-part series of articles discussing the experimental use exemption from infringement in the UK, Section 60 UKPA 1977 in fact provides for three categories of experimental use exemption from infringement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK experimental use exemptions: part 1—the original

15 July 2021 In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

Generics

UK experimental use exemptions: Part 3—the expanded exemption

5 August 2021 In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.

Europe

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

10 August 2021 In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.

More on this story

Big Pharma

UK experimental use exemptions: part 1—the original

15 July 2021 In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

Generics

UK experimental use exemptions: Part 3—the expanded exemption

5 August 2021 In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.

Europe

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

10 August 2021 In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.

More on this story

Big Pharma

UK experimental use exemptions: part 1—the original

15 July 2021 In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

Generics

UK experimental use exemptions: Part 3—the expanded exemption

5 August 2021 In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.

Europe

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

10 August 2021 In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.

More features

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar

MSN scores win in battle with Novartis over heart drug generic

How post-filing data rescued Novo Nordisk’s Ozempic patent in China

Astellas defends blockbuster cancer treatment patent

How to navigate patent term adjustment in China

UK experimental use exemptions: Part 2—the Bolar exemption

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features